You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immune-stimulants and immune modulators
552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020141021
Dec 20201806
Jan 202160020
Feb 2021110025
Mar 2021132029
Apr 202197025
May 202166026
Jun 20210026
Jul 20210019
Aug 20210014
Sep 20210023
Oct 2021146043
Nov 2021112031
Dec 202194018
Jan 2022114016
Feb 20229609
Mar 202246019
Apr 202268033
May 202282011
Jun 2022134014
Jul 2022134019
Aug 202288016
Sep 2022108012
Oct 2022102011
Nov 20226405
Dec 20225007
Jan 20233207
Feb 20234609
Mar 20236009
Apr 202340012
May 20232601
Jun 20233005
Jul 20232806
Aug 20233602
Sep 20233802
Oct 20233405
Nov 20235402
Dec 20234001
Jan 20242601
Feb 20243401
Mar 20241801
Apr 20243208
May 20243405
Jun 20242600
Jul 20242407
Aug 20242802
Sep 20242002
Oct 20242204
Nov 202430010
Dec 20243006
Jan 20253008
Feb 2025004
Mar 2025009
Apr 2025003
May 2025005
Jun 2025003
Total28800638